Reports Interim Phase I/IIa Trial Results for TZ101, a Novel Enzyme Treatment to Enhance Stem Cell Targeting/Engraftment for Improved Cancer Patient Clinical Outcomes
SAN ANTONIO, TX DEC 18 2013.
America Stem Cell, Inc. (ASC) today announces that it has changed its name to Targazyme, Inc. (www.old.targazyme.com). The new name reflects the company’s family of enzyme products aimed at improving cell targeting and engraftment for better efficacy outcomes in stem cell and regenerative medicine.
Phase I/IIa results of Targazyme’s lead product, TZ101, were presented at the American Society of Hematology meeting in New Orleans (Popat et al. Abstract #691, Dec 9). The Phase […]